Patrick F. Smith

Learn More
  • Edward J Gane, Stuart K Roberts, Catherine A M Stedman, Peter W Angus, Brett Ritchie, Rob Elston +11 others
  • 2010
BACKGROUND Present interferon-based standard of care treatment for chronic hepatitis C virus (HCV) infection is limited by both efficacy and tolerability. We assessed the safety, tolerability, and antiviral activity of an all-oral combination treatment with two experimental anti-HCV drugs-RG7128, a nucleoside polymerase inhibitor; and danoprevir, an NS3/4A(More)
  • 1